RT Journal Article
SR Electronic
T1 Trajectories of Neurological Recovery 12 Months after Hospitalization for COVID-19: A Prospective Longitudinal Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.08.22270674
DO 10.1101/2022.02.08.22270674
A1 Frontera, Jennifer A.
A1 Yang, Dixon
A1 Medicherla, Chaitanya
A1 Baskharoun, Samuel
A1 Bauman, Kristie
A1 Bell, Lena
A1 Bhagat, Dhristie
A1 Bondi, Steven
A1 Chervinsky, Alexander
A1 Dygert, Levi
A1 Fuchs, Benjamin
A1 Gratch, Daniel
A1 Hasanaj, Lisena
A1 Horng, Jennifer
A1 Huang, Joshua
A1 Jauregui, Ruben
A1 Ji, Yuan
A1 Kahn, D. Ethan
A1 Koch, Ethan
A1 Lin, Jessica
A1 Liu, Susan B.
A1 Olivera, Anlys
A1 Rosenthal, Jonathan
A1 Snyder, Thomas
A1 Stainman, Rebecca S.
A1 Talmasov, Daniel
A1 Thomas, Betsy
A1 Valdes, Eduard
A1 Zhou, Ting
A1 Zhu, Yingrong
A1 Lewis, Ariane
A1 Lord, Aaron S.
A1 Melmed, Kara
A1 Meropol, Sharon B.
A1 Thawani, Sujata
A1 Troxel, Andrea B.
A1 Yaghi, Shadi
A1 Balcer, Laura J.
A1 Wisniewski, Thomas
A1 Galetta, Steven L.
YR 2022
UL http://medrxiv.org/content/early/2022/02/09/2022.02.08.22270674.abstract
AB Background/Objectives Little is known about trajectories of recovery 12-months after hospitalization for severe COVID.Methods We conducted a prospective, longitudinal cohort study of patients with and without neurological complications during index hospitalization for COVID-19 from March 10, 2020-May 20, 2020. Phone follow-up batteries were performed at 6- and 12-months post-COVID symptom onset. The primary 12-month outcome was the modified Rankin Scale (mRS) comparing patients with or without neurological complications using multivariable ordinal analysis. Secondary outcomes included: activities of daily living (Barthel Index), telephone Montreal Cognitive Assessment (t-MoCA) and Neuro-QoL batteries for anxiety, depression, fatigue and sleep. Changes in outcome scores from 6 to 12-months were compared using non-parametric paired-samples sign test.Results Twelve-month follow-up was completed in N=242 patients (median age 65, 64% male, 34% intubated during hospitalization) and N=174 completed both 6- and 12-month follow-up. At 12-months 197/227 (87%) had ≥1 abnormal metric: mRS>0 (75%), Barthel<100 (64%), t-MoCA≤18 (50%), high anxiety (7%), depression (4%), fatigue (9%) and poor sleep (10%). 12-month mRS scores did not differ significantly among those with (N=113) or without (N=129) neurological complications during hospitalization after adjusting for age, sex, race, pre-COVID mRS and intubation status (adjusted OR 1.4, 95% CI0.8-2.5), though those with neurological complications had higher fatigue scores (T-score 47 vs 44, P=0.037). Significant improvements in outcome trajectories from 6- to 12-months were observed in t-MoCA scores (56% improved, median difference 1 point, P=0.002), and Neuro-QoL anxiety scores (45% improved, P=0.003). Non-significant improvements occurred in fatigue, sleep and depression scores in 48%, 48% and 38% of patients, respectively. Barthel and mRS scores remained unchanged between 6 and 12-months in >50% of patients.Discussion At 12-months post-hospitalization for severe COVID, 87% of patients had ongoing abnormalities in functional, cognitive or Neuro-QoL metrics and abnormal cognition persisted in 50% of patients without a prior history of dementia/cognitive abnormality. Only fatigue severity differed significantly between patients with or without neurological complications during index hospitalization. However, significant improvements in cognitive (t-MoCA) and anxiety (Neuro-QoL) scores occurred in 56% and 45% of patients, respectively, between 6- to 12-months. These results may not be generalizable to those with mild/moderate COVID.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the NYU Grossman School of Medicine Institutional Review Board. All patients or their surrogates provided consent for participation.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors